Phase I trial of volasertib, a Polo-like kinase inhibitor, in Japanese patients with acute myeloid leukemia by Kobayashi Yukio et al.
Phase I trial of volasertib, a Polo-like kinase inhibitor,
in Japanese patients with acute myeloid leukemia
Yukio Kobayashi,1 Takahiro Yamauchi,2 Hitoshi Kiyoi,3 Toru Sakura,4 Tomoko Hata,5 Kiyoshi Ando,6
Aiko Watabe,7 Akiko Harada,8 Tillmann Taube,9 Yasushi Miyazaki5 and Tomoki Naoe10
1Hematology Division, National Cancer Center Hospital, Tokyo; 2Department of Hematology and Oncology, University of Fukui, Fukui; 3Department of
Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya; 4Leukemia Research Center, Saiseikai Maebashi Hospital, Gunma;
5Department of Hematology, Nagasaki University Hospital, Nagasaki; 6Department of Hematology and Oncology, Tokai University School of Medicine,
Kanagawa; 7Clinical Trial Management Department, Nippon Boehringer Ingelheim Co., Ltd, Tokyo; 8Clinical PK/PD Department, Nippon Boehringer
Ingelheim Co., Ltd, Hyogo, Japan; 9Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany; 10National Hospital Organization Nagoya Medical
Center, Nagoya, Japan
Key words
Acute myeloid leukemia, clinical trial phase I, Japanese,
maximum tolerated dose, Polo-like kinase 1
Correspondence
Yukio Kobayashi, National Cancer Center Hospital, 5-1-1
Tsukiji, Chuo-ku, Tokyo 104-0045, Japan.
Tel: +81-33542-2511; Fax: +81-33542-3815;
E-mail: ykkobaya@ncc.go.jp
Funding Information
Study 1230.26 was sponsored by Nippon Boehringer
Ingelheim Co., Ltd.
Clinicaltrials.gov: NCT01662505
Received August 18, 2015; Accepted September 6, 2015
Cancer Sci 106 (2015) 1590–1595
doi: 10.1111/cas.12814
This phase I trial conducted in Japanese patients with acute myeloid leukemia
evaluated the safety, maximum tolerated dose and pharmacokinetics of volaser-
tib (BI 6727), a selective Polo-like kinase inhibitor. The primary endpoints were
the maximum tolerated dose of volasertib and the incidence of dose-limiting tox-
icities. Secondary endpoints were best response and remission duration. Other
endpoints included safety and pharmacokinetics. Patients who were ineligible for
standard induction therapy or with relapsed or refractory disease received vola-
sertib monotherapy as a 2-h infusion on days 1 and 15 of a 28-day cycle, with
dose escalation following a 3 + 3 design. A total of 19 patients were treated with
three volasertib doses: 350, 400 and 450 mg. One patient receiving volasertib
450 mg reported a dose-limiting toxicity of grade 4 abnormal liver function test
and 450 mg was determined as the maximum tolerated dose. The most fre-
quently reported adverse events were febrile neutropenia (78.9%), decreased
appetite (42.1%), nausea and rash (36.8% each), and sepsis, fatigue, hypokale-
mia, stomatitis and epistaxis (26.3% each). Best responses were complete remis-
sion (n = 3), complete remission with incomplete blood count recovery (n = 3)
and partial remission (n = 1). The median remission duration of the six patients
with complete remission or complete remission with incomplete blood count
recovery was 85 days (range 56–358). Volasertib exhibited multi-compartmental
pharmacokinetic behavior with a fast distribution after the end of infusion fol-
lowed by slower elimination phases. Volasertib monotherapy was clinically man-
ageable with acceptable adverse events and anti-leukemic activity.
A cute myeloid leukemia (AML) is a heterogeneous clonaldisorder of hematopoietic progenitor cells and represents
the most common form of acute leukemia in adults.(1) Standard
therapy for AML includes the nucleoside analog cytarabine in
combination with an anthracycline and there have been few
changes to this primary therapy over the past three decades.
Therapeutic outcomes for younger patients with AML have
improved over the past 30 years, possibly due to improve-
ments in supportive care, for example, the use of antibiotics;(2)
however, durable cures occur in the minority of patients with
standard therapy.(3) For newly diagnosed older patients, clini-
cal outcomes are worse because many cannot tolerate intensive
remission induction chemotherapy and the disease is more
often chemotherapy-resistant.(2) Patients with relapsed ⁄ refrac-
tory AML also have a poor prognosis.(4)
The current National Comprehensive Cancer Network guide-
lines recommend participation in clinical trials as the first
choice for older patients with untreated AML, and participa-
tion in clinical trials is strongly preferred for patients with
relapsed ⁄ refractory disease.(1) Along with advances in under-
standing the biology of AML, therapies that have novel mech-
anisms of action and can be tolerated by older patients are
needed to improve outcomes for patients with AML.(3)
The serine ⁄ threonine kinase Polo-like kinase 1 (PLK1) con-
trols several key steps during mitosis.(5,6) PLK1 overexpression
has been demonstrated in various human cancers, including
AML,(7–9) and a potential role for PLK1 overexpression in car-
cinogenesis has been shown both in vitro and in vivo,(7,10)
making PLK1 an attractive target for novel therapeutic
approaches in cancer.(5)
Volasertib (an investigational agent) is a selective and potent
cell cycle kinase inhibitor that induces mitotic arrest and apop-
tosis by targeting PLK.(11) Volasertib has been shown to selec-
tively inhibit PLK1 and, to a lesser extent, PLK2 and PLK3,
but does not inhibit more than 50 unrelated kinases tested.(11)
Preclinical studies have shown that targeting PLK with vola-
sertib leads to cell cycle arrest with abnormal mitotic figures
(polo arrest) and subsequent cell death by apoptosis.(11) In
addition, volasertib has shown anti-tumor efficacy in multiple
preclinical models of AML, including bone marrow samples in
short-term culture as well as subcutaneous and disseminated
in vivo models in immune-deficient mice.(12)
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Volasertib has been previously investigated as monotherapy
in a phase I trial in White patients with relapsed or refractory
AML who are ineligible for intensive therapy(13) and demon-
strate a clinically manageable safety profile at maximum toler-
ated dose (MTD) with anti-leukemic activity.(13) The phase I
trial reported here was conducted to evaluate the MTD, the
safety, the tolerability and the pharmacokinetics (PK) of vola-
sertib, administered once every 2 weeks as monotherapy, in
Japanese patients with AML.
Materials and Methods
Trial design. This was a phase I, open-label, dose-escalation
study conducted in six centers in Japan (NCT01662505; Study
1230.26) that enrolled adults with relapsed ⁄ refractory or
untreated AML who were ineligible for standard induction
therapy. The primary endpoints of this trial were the MTD of
volasertib and the incidence of dose-limiting toxicities (DLT).
Secondary endpoints were best response (complete remission
[CR], CR with incomplete blood count recovery [CRi] and
partial remission [PR]) according to the criteria published by
the International Working Group and European Leukemia Net
and remission duration. Other endpoints included the incidence
and intensity of adverse events (AE) graded according to the
Common Terminology Criteria for Adverse Events (CTCAE),
version 3.0, and safety laboratory parameters. The trial was
conducted in compliance with the principles laid down in the
Declaration of Helsinki, in accordance with the International
Conference on Harmonisation Harmonised Tripartite Guideline
for Good Clinical Practice (GCP), and in accordance with rele-
vant Boehringer Ingelheim standard operating procedures and
the Japanese GCP regulation. All participating patients gave
written informed consent.
Patients. Patients were required to be aged ≥18 years with
relapsed ⁄ refractory AML or untreated AML considered not
suitable for standard induction therapy according to the investi-
gator’s judgment. The diagnosis of AML was made according
to World Health Organization classification, and patients were
required to have an Eastern Co-operative Oncology Group
(ECOG) performance status ≤2 at screening and to have signed
informed consent consistent with the Japanese GCP. Patients
were excluded if they had: a diagnosis of acute promyelocytic
leukemia, a third or later relapse, prior hematopoietic stem cell
transplantation, an additional malignancy that required treat-
ment, clinical evidence of active central nervous system leuke-
mia at the time of screening, a resting left ventricular ejection
fraction <50% at the time of screening, a clinically relevant
QT prolongation (e.g. long QT syndrome, QTcF >470 ms), a
treatment with systemic therapy for the primary disease within
14 days (except for hydroxyurea), lack of recovery from any
acute toxicities or clinically significant AE pertinent to the
prior systemic therapy, aspartate aminotransferase (AST) or
alanine aminotransferase (ALT) >2.5 times the upper limit of
normal, total bilirubin >2.0 mg ⁄dL, or serum creatinine
>2.0 mg ⁄dL.
Treatments. Patients received volasertib as monotherapy on
days 1 and 15 of a 28-day cycle via intravenous drip infusion
over 2 h. Dose escalation followed a 3 + 3 design with a start-
ing dose of volasertib 350 mg (level 1) per administration.
The duration of one treatment cycle was 28 days, and a subse-
quent cycle could be started on day 29 unless study drug-re-
lated AE necessitated an additional recovery period. If a DLT
occurred, the treatment was interrupted until recovery and
resumed at a reduced dose. To allow close safety monitoring,
all patients were hospitalized during the first treatment cycle
or until the investigator considered it appropriate to manage
the patient on an outpatient basis. The use of growth factors
was allowed as per institutional standards. Prophylactic anti-
emetics were not requested per protocol but were allowed if
medically indicated. Patients were allowed to remain on the
study treatment for additional treatment cycles if the following
criteria for retreatment were met: recovery from any DLT
(cycle 1) ⁄DLT-equivalent AE (cycle 2 onwards) to CTCAE
grade ≤2 or baseline, whichever was higher, except for QTcF,
which was required to be CTCAE grade ≤1 before retreatment;
absence of any discontinuation criteria; and patient’s re-con-
sent to additional treatment cycles (before starting cycle 2).
Assessments. The frequencies of AE were tabulated by the
Medical Dictionary for Regulatory Activities system organ
class and preferred term and CTCAE grade for each dose
cohort. AE were also classified by the causality relationship
with the study drug. Any CTCAE grade ≥3 non-hematologic
AE occurring during cycle 1, which were considered by the
investigator to be related to the study treatment qualified as
DLT except for: untreated nausea or vomiting of any grade;
grade 3 untreated diarrhea that could be sufficiently treated
and reduced to grade ≤2; grade 3 febrile neutropenia, or
grade 3 infection with grade 3 or 4 neutrophils; any laboratory
abnormality, which is not considered clinically significant by
the investigator or resolves spontaneously or can be recovered
with appropriate treatment within 5 days; and CTCAE grade 3
tumor lysis syndrome.
Electrocardiograms (ECG) were performed and QTcF calcu-
lated with every infusion of volasertib (days 1 and 15) before
the start and shortly before the end of the infusion. In cycle 1,
additional ECG were performed at 4, 8 and 24 h post-infusion
on day 1.
Blood samples for PK analysis were collected in cycle 1
pre-dose, and 1, 2, 3, 4, 8, 24, 96, 144, 216 and 336 h after
the start of the first infusion and pre-dose, 1 and 2 h after the
start of the second infusion on day 15. Volasertib and the
metabolite CD 10899 plasma concentrations were determined
by a validated high performance liquid chromatography, tan-
dem mass spectrometry assay. The PK parameters were calcu-
lated by standard non-compartmental methods and analyses
were performed using WinNonlin (Pharsight, Mountain View,
CA, USA).
Response was evaluated according to the International
Working Group criteria(14) and European Leukemia Net rec-
ommendations.(15) Response was assessed in the peripheral
blood and in the bone marrow. In case of extramedullary man-
ifestations of leukemia, assessment by imaging, as necessary,
was used to complement the blood and bone marrow assess-
ment of response.
A data cut-off of 6 June 2014 was used for the safety analy-
ses, 26 June 2014 for the PK analyses and 12 March 2015 for
the efficacy analyses. All the analyses of this trial were
descriptive; hence, no statistical model was adopted in this
trial.
Results
A total of 24 patients were enrolled between August 2012 and
March 2014, and 19 patients were treated, receiving at least
one dose, at the following volasertib dose levels: cohort 1,
350 mg (n = 7); cohort 2, 400 mg (n = 4); and cohort 3,
450 mg (n = 8). The remaining five patients who did not receive
the trial medication failed to match the inclusion criteria. By the
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data cut-off, 16 patients (84.2%) had terminated treatment with
trial medication, with the most frequent reason for discontinua-
tion being progressive disease (nine patients, 47.4%).
The patient demographics and baseline disease characteris-
tics are summarized in Table 1. The median age was
73.0 years (range 53–86 years) and the ECOG performance
status was 1 for the majority of patients (11 patients, 57.9%).
The disease status was refractory in seven patients (36.8%),
relapsed in six patients (31.6%), both refractory and relapsed
in two patients (10.5%) and untreated in four patients (21.1%).
Patients received a median of two (range 1–10) cycles of ther-
apy and the median therapy duration was 81 days (range 23–
486 days).
Dose-limiting toxicities. As per the study design, any patients
who could not receive treatment on day 15 of cycle 1 for rea-
sons other than DLT were not evaluable for MTD analysis. To
fulfill the 3 + 3 design, a total of four patients who were not
evaluable had to be replaced for MTD determination (one pa-
tient [350 mg cohort 1] did not receive the second dose
because of early withdrawal due to progressive disease;
three patients [1 in the 400-mg cohort 2 and 2 in the 450-mg
cohort 3] missed the second dose because of AE that did not
qualify as DLT). No DLT were reported in cycle 1 in the 350-
mg or 400-mg cohort.
One DLT was reported in cohort 3 cycle 1 at the 450-mg
volasertib dose level in 1 of the 6 evaluable patients. This
patient experienced a DLT of grade 4 abnormal liver function
test in cycle 1. The patient was an 80-year-old male and had
elevated transaminases (AST: 39 IU ⁄L [reference 13–33 IU
⁄L], ALT: 64 IU ⁄L [reference 6–30 IU ⁄L], total bilirubin:
0.4 mg ⁄dL [reference 0.3–1.2 mg ⁄dL]) 2 days before the study
medication was started. On day 9 of cycle 1, an increase of
transaminases was observed (AST: 131 IU ⁄L, ALT: 116 IU ⁄L,
total bilirubin: 1.1 mg ⁄dL) and, on day 11, the patient’s
transaminases and bilirubin increased further (AST: 764 IU ⁄L,
ALT: 711 IU ⁄L, total bilirubin: 2.6 mg ⁄dL) and a DLT of
grade 4 abnormal liver function test was recorded. By day 16,
transaminases and bilirubin were improved and became equiv-
alent to CTCAE grade 3 (AST: 156 IU ⁄L, ALT: 450 IU ⁄L,
total bilirubin: 3.8 mg ⁄dL). However, on day 17, the labora-
tory parameters were not improved to the level fulfilling the
retreatment criteria; therefore, the second infusion of volasertib
was suspended. By day 29 (cycle 2, day 1), the laboratory
parameters indicating liver damage were mostly normalized
(AST: 15 IU ⁄L, ALT: 38 IU ⁄L, total bilirubin: 1.0 mg ⁄dL).
According to dose-reduction criteria, treatment with volasertib
in cycle 2 was started at a reduced dose (400 mg). On day 38
(cycle 2, day 10), the liver parameters were stable within the
reference range and the patient was considered to have recov-
ered from the DLT.
Volasertib 450 mg was the highest dose level planned for
the trial; therefore, dose escalation was ceased at this level and
450 mg was determined as the MTD of volasertib administered
intravenously on days 1 and 15 in 28-day cycles in Japanese
patients with AML.
Safety. Across all treatment cycles, all 19 patients reported
at least one AE irrespective of cause and one drug-related AE;
94.7% of patients reported CTCAE of grade ≥3. The most
common AE (>20%) were febrile neutropenia (78.9%),
decreased appetite (42.1%), nausea and rash (36.8% each),
sepsis, fatigue, hypokalemia, stomatitis and epistaxis (26.3%
each), vomiting and pyrexia (21.1% each), with no apparent
trends for dose-related increase in frequency. AE by dose, all
grades and grades 3 and 4, irrespective of relationship, occur-
ring in ≥15% of patients overall are summarized in Table 2.
Grade 4 AE were reported by one of seven patients in the
350-mg cohort 1 (neutropenia and thrombocytopenia), two of
four patients in the 400-mg cohort 2 (neutropenia and throm-
bocytopenia), and three of eight patients in the 450-mg
cohort 3 (neutropenia, hypokalemia and abnormal liver func-
tion test). No fatal (grade 5) AE were reported. No patient
experienced AE that led to discontinuation of the study medi-
cation in any dose cohort. Dose reductions occurred in 2 out
of 19 patients after cycle 1 at the investigator’s discretion and
not in accordance with the protocol. The mean (standard devi-
ation) treatment dose per cycle was 594 mg (134 mg) for the
350-mg cohort 1, 685 mg (93 mg) for the 400-mg cohort 2,
and 706 mg (219 mg) for 450-mg cohort 3.
The ECG analysis showed a maximum increase in the mean
QTcF interval at 2 h after the start of the volasertib infusion.
After the initial increase at 2 h, the mean QTcF intervals
tended to decrease to near baseline levels by 24 h post-dosing
in all dose cohorts. A >60 ms QTcF interval increase at the
end of infusion compared to the QTcF interval prior to infu-
sion was only observed in two patients treated with volasertib
450 mg cohort 3. No QTcF intervals >500 ms were reported.
Pharmacokinetics. The PK profile of volasertib demonstrated
a general increase in mean plasma concentration until the end
of infusion, followed by a rapid decline (Fig. 1). By 24 h after
administration, the mean plasma concentration of volasertib
decreased to <10% of the maximum plasma concentration.
Volasertib exhibited multi-compartmental PK behavior. Expo-
sure to volasertib increased dose-proportionally within the dose
range tested. PK parameters of volasertib and its major
metabolite, CD 10899, after the first infusion of volasertib
350, 400 and 450 mg are summarized in Table 3. The geomet-
ric mean (gMean) elimination half-life ranged from 108 to
130 h and was dose-independent. The gMean volume of distri-
bution of volasertib ranged from 3540 to 4720 L, suggesting
Table 1. Patient demographic and baseline disease characteristics
Volasertib (N = 19)
Median age, years (range) 73 (53–86)
<65 years 2 (10.5)
65–75 years 9 (47.4)
≥75 years 8 (42.1)
Male ⁄ female, n (%) 7 (36.8) ⁄ 12 (63.2)




Disease state, n (%)
Refractory 7 (36.8)
Relapsed 6 (31.6)
Relapsed and refractory 2 (10.5)
Untreated 4 (21.1)
AML considered secondary, n (%)† 7 (36.8)
Preceding MDS 4 (21.1)






†Percentages do not sum to total due to rounding. AML, acute mye-
loid leukemia; ECOG PS, Eastern Co-operative Oncology Group Perfor-
mance Score; MDS, myelodysplastic syndrome.
© 2015 The Authors. Cancer Science published by Wiley Publishing Asia Pty Ltd
on behalf of Japanese Cancer Association.
Cancer Sci | November 2015 | vol. 106 | no. 11 | 1592
Original Article
Phase I of volasertib in Japanese www.wileyonlinelibrary.com/journal/cas
extensive distribution of volasertib into tissues and ⁄or organs.
Total plasma clearance was moderate and ranged from 606 to
669 mL ⁄min. The gMean exposure ratios of the metabolite
CD 10899 to volasertib expressed as RAUC0–tz,M/P after the
first volasertib administration ranged from 13.3% to 15.0%.
Efficacy. All 19 patients were evaluable for response, with
the results summarized in Table 4. A total of seven patients
(36.8%) achieved the best response of CR, CRi or PR. One of
seven patients in the 350-mg cohort achieved a CR, two of
four patients in the 400-mg cohort achieved a CRi, and four
of eight patients in the 450-mg cohort achieved CR (n = 2),
CRi (n = 1) or PR (n = 1). The remission duration of the
six patients with CR or CRi ranged from 56 to 358 days (me-
dian 85 days). Out of seven patients with a CR, CRi or PR,
the baseline cytogenetic data were available for five patients:
one patient with CR had a complex karyotype including 5
⁄del(5q), del(q13), 17 ⁄del(17p), and other abnormality at
baseline; one patient with CRi had a complex karyotype
including 7 ⁄del(7q) and other abnormality at baseline; the 3
remaining patients had normal karyotype at baseline. Of the
seven patients who achieved CR ⁄CRi ⁄PR, all patients were
relapsed or refractory to previous treatments for AML. One
patient (male aged 69 years with primary refractory M2
de novo AML and complex karyotype) showed a rapid reduc-
tion in peripheral blast counts and aplastic bone marrow after
cycle 1. Granulocyte-colony stimulating factor was used at the
end of cycle 2 and during cycle 3 to support blood count
recovery. This patient achieved a CR after cycle 3, which was
maintained for 358 days.
Discussion
This phase I trial was the first to investigate volasertib
monotherapy in Japanese patients with AML ineligible for
standard therapy. The highest planned dose of volasertib
(450 mg) administered intravenously on days 1 and 15 in 28-
day cycles was determined to be tolerable, with one patient
experiencing a DLT at 450 mg of reversible grade 4 liver
function test abnormality. Dose escalation was limited to
450 mg, which was the MTD reported in a phase I study of
volasertib monotherapy in White patients.(13) In contrast to the
present study, DLT of mucosal inflammation and pyrexia were
reported in White patients at 400 and 450 mg, respectively.
The AE profile of volasertib monotherapy in Japanese
patients was considered clinically manageable and acceptable.
CTCAE grade 3 febrile neutropenia, sepsis, decreased appetite
and grade 4 neutropenia were among the most frequently
reported severe AE with no apparent trends for dose-related
increases in frequency. Grade 4 AE were mainly hematologic
(neutropenia, thrombocytopenia). The overlap between the
expected side effects of volasertib and the cardinal symptoms
of AML, including myelosuppression, blood cytopenias, neu-
tropenic fever and infection, make the assessment of AE with
regard to relatedness challenging. These safety results are as
expected from the mode of action of volasertib and the under-
lying disease, and are also in line with what was expected
from the phase I ⁄ II trial in White patients with AML.(13,16)
Because volasertib is expected to add on to the AML-related
Table 2. AEs by dose, all grades and grade 3 and 4 AEs irrespective of relationship, occurring in ≥15% of patients overall


























Sepsis 2 2 – 1 1 – 2 2 – 5 5 –
Infection 2 2 – – – – 1 – – 3 2 –
Febrile neutropenia 5 5 – 3 3 – 7 6 – 15 14 –
Neutropenia 1 – 1 1 – 1 1 – 1 3 – 3
Decreased appetite 5 1 – 1 – – 2 2 – 8 3 –
Hypokalemia 3 1 – – – – 2 – 1 5 1 1
Hyperuricemia 3 – – – – – – – – 3 – –
Hypoalbuminemia 2 – – – – – 1 – – 3 – –
Epistaxis 1 – – 2 – – 2 – – 5 – –
Nausea 1 – – 2 – – 4 – – 7 – –
Stomatitis 2 – – 1 – – 2 – – 5 – –
Vomiting 1 – – 1 – – 2 – – 4 – –
Rash – – – 4 – – 3 – – 7 – –
Fatigue 1 – – 3 – – 1 – – 5 – –
Pyrexia 2 – – – – – 2 – – 4 – –
Blood creatinine
increased
1 – – 2 – – – – – 3 – –
Data cut–off June 6, 2014. AE, adverse event.
Fig. 1. Arithmetic mean plasma concentration of volasertib over
time. BS, free base.
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blood count changes and complications thereof, these AE
require close monitoring and management through supportive
care, prophylaxis and prompt start of infection treatment, if
necessary.
Kinase inhibitors, including volasertib, are known to cause a
reversible prolongation of the QT interval.(17,18) The magnitude
of QTcF prolongation at the end of the volasertib infusion
tended to be greatest in the 450 mg cohort-3, and returned to
near baseline within 24 h. No patients in any cohort developed
clinically relevant abnormalities in cardiologic assessment dur-
ing treatment with volasertib.
Volasertib plasma concentration increased until the end of
infusion and declined rapidly after the end of infusion. Vola-
sertib exhibited multi-compartmental PK behavior with fast
distribution after the end of infusion followed by slower elimi-
nation phases and exposure increased dose-proportionally
within the dose range tested. The volasertib exposure observed
in Japanese patients appears to be comparable or slightly
higher than exposure reported in studies with White, Asian
and Japanese patients with solid tumors (Nokihara et al., 2015,
manuscript in preparation).(19,20) The difference in exposure
could be due to differences in weight between the study popu-
lations; however, patient numbers are low and so this observa-
tion should be interpreted with caution. Overall, the PK of
volasertib in Japanese patients with AML are within the
expected range observed in the previous trials in Japanese,
Asian and White patients (Nokihara et al., 2015, manuscript in
preparation).(19,20)
In a preliminary evaluation of best response, volasertib
monotherapy demonstrated anti-leukemic activity in Japanese
patients with AML. The best response of CR, CRi, or PR was
achieved by 7 out of 19 treated patients (36.8%) and the
remission duration of the six patients with CR or CRi ranged
from 56 to 358 days; one patient was receiving treatment in
CR at the time of analysis. Given the poor prognosis of the
trial population, this result was considered to indicate anti-leu-
kemic activity of volasertib, supporting PLK as a potential
therapeutic target in AML.
In conclusion, volasertib monotherapy at the investigated
doses showed a clinically manageable safety profile and anti-
leukemic activity. Overall, the safety and efficacy results, as
well as the determined MTD, were consistent with the previ-
ous study in White patients with AML(19) and justify participa-
tion of Japanese patients in global volasertib AML trials
without dose modification.
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Volasertib CD 10899 Volasertib CD 10899 Volasertib CD 10899
AUC0–tz, ngh ⁄mL 7810 (29.2) 1080 (70.3) 9340 (48.8) 1280 (34.8) 11400 (20.5) 1750 (56.4)
AUC0–∞, ngh ⁄mL 8720 (27.8) 1500 (88.0) 10400 (54.7) 1680 (50.6) 12400 (22.8) 2050 (57.4)
AUC0–∞,norm, ngh ⁄mL ⁄mg 24.9 (27.8) 4.30 (88.0) 25.9 (54.7) 4.19 (50.6) 27.5 (22.8) 4.55 (57.4)
Cmax, ng ⁄mL 756 (43.2) 8.45 (80.7) 762 (34.8) 8.46 (43.3) 1060 (28.6) 15.6 (78.3)
tmax,† h 1.97 (0.967–2.15) 23.7 (3.03–96.0) 1.05 (0.867–2.05) 16.0 (7.98–120) 1.53 (0.967–2.20) 7.99 (3.97–96.0)
t1/2, h 117 (23.3) 167 (43.0) 130 (21.6) 168 (43.2) 108 (26.4) 118 (31.5)
CL, mL ⁄min 669 (27.8) – 643 (54.7) – 606 (22.8) –
Vss, L 4430 (33.5) – 4720 (14.5) – 3540 (28.0) –
RAUC0–tzM/P, % – 13.4 (78.0) – 13.3 (30.8) – 15.0 (44.4)
RAUC0–∞M/P, % – 16.8 (101) – 15.8 (19.9) – 16.1 (42.0)
†Median (range). gMean, geometric mean; gCV%, geometric coefficient of variation; AUC, area under the concentration–time curve of the ana-
lyte in plasma; AUC0–tz, AUC of the analyte in plasma over the time interval from 0 to time of the last quantifiable plasma concentration;
AUC0–∞, AUC of the analyte in plasma over the time interval from 0 extrapolated to infinity; Cmax, maximum plasma concentration; tmax, time
from dosing to the maximum concentration of the analyte in plasma; t1/2, terminal half-life; CL, total plasma clearance; Vss, apparent volume of
distribution after intravenous infusion at steady state; norm, dose normalized; RAUC0–∞M/P, ratio of the AUC in plasma of metabolite versus par-
ent over the time interval from 0 extrapolated to infinity; RAUC0–tzM/P, ratio of the AUC in plasma of metabolite versus parent over the time
interval from 0 to time of the last quantifiable plasma concentration.












Best overall response, n (%)
CR 1 – 2 3 (15.8)
CRi – 2 1 3 (15.8)
PR – – 1 1 (5.3)
SD 3 2 3 8 (42.1)
PD 3 – 1 4 (21.1)
Remission duration†
CR ⁄ CRi, n 1 2 3 6
Median, days
(range)
358 72 (70–74) 96 (56–262) 85 (56–358)
†One patient was receiving ongoing treatment in CR at the time of
analysis. Data cut-off March 12, 2015. CR, complete remission; CRi, CR
with incomplete blood count recovery; PD, progressive disease; PR,
partial remission; SD, stable disease.
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